Navigation Links
Alnylam Announces Advancement of a New RNAi Therapeutic Development,Program for the Treatment of Liver Cancer

a rodent model;

-- Silencing of KSP mRNA in vivo by greater than 50 percent after a single injection of a KSP-specific siRNA in a rodent model; and

-- Halting of human cancer cell proliferation in vitro when KSP was silenced by a target-specific siRNA.

Alnylam's RNAi therapeutic, ALN-VSP01, is comprised of two small interfering RNAs, or siRNAs, the molecules that mediate RNAi. Each siRNA targets a distinct and well-validated gene in the growth and proliferation of tumors: VEGF, a key mediator of tumor angiogenesis; and KSP, a protein required for cell division that, when inhibited, leads to cell arrest and cell death in dividing cells. ALN-VSP01 is formulated using Alnylam's novel liposomal formulation technology, which has been used to achieve delivery of siRNAs to cells of the liver and efficient silencing of genes expressed in that organ. Liposomal delivery can also be optimized for delivery to other organs and tumor types, such that ALN-VSP01 may ultimately have potential for a range of solid tumors. Alnylam's collaborator, Inex Pharmaceuticals Corporation, is manufacturing the lipid-based formulation as the company prepares for pre-IND toxicology studies with ALN-VSP01.

"Despite many advances in the treatment of cancer with targeted small molecules and antibody therapeutics, the clinical impact of these therapies is generally measured in only months of survival benefit. New modalities like RNAi therapeutics offer the potential to advance cancer therapy to a whole new level," said George D. Demetri, M.D., of Dana-Farber Cancer Institute and Harvard Medical School. "I'm encouraged by Alnylam's pre-clinical data demonstrating the ability to silence disease pathway genes with delivery of RNAi therapeutics, and believe that the application of this approach for the treatment of primary and secondary liver cancers holds considerable promise."

About Liver Cancer

Primary liver cancer is cancer that forms in the tissues of the l
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Alnylam Reports Results of Human Experimental Infection Model with Respiratory Syncytial Virus
2. Alnylam and Stanford University Scientists Discover New Role for microRNAs (miRNAs) in T Cell Biology and Immunity
3. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study

Post Your Comments:
(Date:11/6/2009)...Nov. 6 GeoVax Labs, Inc...mpany"), an Atlanta-based, biopharmaceutical compa...y HIV-1 (Human Immunodeficiency Virus) and other i...r 2009 financial results and provided an operation...and Chief Executive Officer commented, "We are ple...
(Date:11/6/2009)..., November 6 , - Trial Wi...d for the,Treatment of Multi-Resistant Staphylococ... speciality pharmaceutical company focused on the ...igned to overcome the significant global,problem o...ost advanced oral,antibacterial NXL103 (flopristin...
(Date:11/5/2009)...ntario, Nov. 5 Helix Bio...unced today that its Phase II trial of Topical Int...warts (AGW) has completed patient enrollment, with...e trial. ,, The double-blind and placebo-contro...s in Germany and Sweden. Patients participating i...
Breaking Medicine Technology:GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 2GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 3GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 4GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 5GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 6GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 7GeoVax Labs, Inc. Provides Third Quarter 2009 Financial Results and Operational Update 8Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 2Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 3Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 2Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 3Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 4Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 5Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 6Nanoparticle delivered 26apos 3BSuicide 26apos 3B Genes Slowed Ovarian Tumor Growth 53171 1Nanoparticle delivered 26apos 3BSuicide 26apos 3B Genes Slowed Ovarian Tumor Growth 53171 2Nanoparticle delivered 26apos 3BSuicide 26apos 3B Genes Slowed Ovarian Tumor Growth 53171 3First genetically engineered malaria vaccine to enter human trials 13267 1First genetically engineered malaria vaccine to enter human trials 13267 2U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 1U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 2U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 3U S Federal Trade Commission to Challenge Thoratecs Proposed Acquisition of HeartWare International 13265 4
(Date:11/8/2009)... , New book called "...macy" by Dr. Roberto Giraldo shows that AIDS ...sure to a variety of so-called immune system stres..., nutritional and most of all, emotional. , ..., 2009 -- From Nov. 6 – 8, 2009, cell biolog...
(Date:11/8/2009)... , A jury of 8 people in ...te County woman $2,300,000 in pain and suffering f...renney, James Tallman and Alicia Nocera of Thomas ... behalf of the plaintiff, Vita Monestersky and aga...e an emergency total abdominal hysterectomy at age...
(Date:11/8/2009)... , WASHINGTON, Nov. 7 /PRNewswire-USNewswire/...fordable Health Care for America Act, which will m...d insurance companies accountable and increase acc...gh a public option. ,, "Teddy Roosevelt, FDR an...ram Director Alan Charney. "Today,s vote ranks amo...
(Date:11/8/2009)... , AARP Praises House Passage of Health Care...rengthen Medicare, improve coverage for all Americ... -- Today, the United States House of Representati...are reform legislation that would strengthen Medic...e companies that prices millions of Americans out ...
(Date:11/7/2009)... , WASHINGTON, Nov. 7 /PRNewswire-USNewswire/...Health Insurance Plans (AHIP), released the follow... ,, "Health plans strongly support comprehensiv...his discussion by proposing a complete overhaul of...ar, we proposed guaranteed coverage, elimination o...
Breaking Medicine News(10 mins):Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 2Health News:Revolutionary New Views on AIDS Highlight the Rethinking AIDS 2009 Congress; Emotional Issues can be a Significant Contributing Factor 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:AHIP Statement on House Passage of H.R. 3962 2
...ories of unpleasant experiences with unhealthy foo... Elizabeth Loftus of the University of Califo...ers that they had been sick after eating strawberr...eedback on their questionnaires that suggested the...
...rs have developed a portable la-chip called Genoty...he flu virus within hours and help the doctors to ...archers from University of Michigan, the Genotyper...globe. The process for identifying the flu ty...
... delivered their firstborn by caesarean were less ...ontaneous natural delivery says a new British stud...at the University of Aberdeen, Britain, followed w...000 women found that 66.9 percent of mothers under...
...ities are pouring cold water on hopes for a new dr...The Food and Drug Administration (FDA) wants more ...rocter & Gamble in order to find out what long-ter...sexual appetites to women struggling with low desi...
...ofessionals have been recently notified that some ...on may malfunction due to a build-up of moisture /...ion designs that have not been sold or implanted i...Plus II, Intelis II, and Contak TR. The defe...
...s fast pace world it is very difficult to remain c...re affected by stress. Stress has been found to in...y psychological stress has been found to delay hea...psychological stress, brought on by confinement, d...
Other Medicine News:Health News:Unpleasant Memory of Food could Be Used to Treat Obesity 2Health News:New Tools To Identify Flu Strains 2Health News:FDA Diminish Hopes On ‘Female Viagra 2Health News:FDA Diminish Hopes On ‘Female Viagra 3Health News:Wound healing affected by Psychological stress 2
Active Ankle Orthosis(Trainers)
Bledsoe M-Brace Ankle Support
Bledsoe Short Term Boot
Bledsoe Low Cost Boot
Medicine Products: